Alcoa (NYSE:AA) had its neutral rating reissued by analysts at Zacks. They currently have a $17.00 target price on the stock.
Apollo Education Group (NASDAQ:APOL) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $31.00 price target on the stock. Zacks’ analyst wrote, “Apollo Education beat the Zacks Consensus Estimate for both earnings and revenues in the third quarter of fiscal 2014. However, earnings of $0.61 per share declined 27.6% year over year as a relatively better top-line performance was offset by weaker margins. Revenues declined 15.5% due to enrollment shortfall. Apollo Education’s enrollment trends have remained weak for several quarters now due to lower demand and competitive pressures. Encouragingly, however, starts improved sequentially in all the three quarters of 2014. Moreover, Apollo’s accelerated efforts to right-size its business through significant layoffs and campus closings gives competitive advantage. Also, growth enhancing investments, innovation and recent price cuts should improve student value proposition and retention rates. Though we believe these turnaround efforts should eventually improve enrollment trends and boost margins, enrollments are unlikely to return to positive growth in the near future.”
Bed Bath & Beyond (NASDAQ:BBBY) had its average rating reiterated by analysts at ISI Group. ISI Group currently has a $60.00 target price on the stock.
Citigroup (NYSE:C) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $51.00 price target on the stock. Zacks’ analyst wrote, “Continuing the positive note, Citigroup reported impressive second-quarter 2014 results. Adjusted earnings per share of $1.24 surpassed the Zacks Consensus Estimate of $1.08. However, earnings were below the year-ago figure by $0.01. Notably, prior to the earnings release, Citigroup struck a deal with the U.S. Department of Justice (DOJ), several state attorneys general (State AGs) and the Federal Deposit Insurance Corporation (the FDIC) worth $7 billion. Including credit valuation adjustment (CVA) and debt valuation adjustment (DVA) impact along with charges worth $3.8 billion ($3.7 billion after-tax) related to the mortgage deal, the company reported net income of $0.03 per share. Though revenues declined, on the whole, its profit level outpaced expectations. After reviewing the results, we are maintaining our Neutral recommendation on the shares. “
Canadian Natural Resource (NYSE:CNQ) had its neutral rating reiterated by analysts at Zacks. The firm currently has a $47.00 price target on the stock. Zacks’ analyst wrote, “We are maintaining our Neutral investment thesis on Canadian Natural Resources, reflecting a balanced risk/reward profile. The company’s large, diversified oil and gas asset bases, together with international exposure and a well-balanced blend of conventional and unconventional prospects, provides a buffer against uncertainties in the sector. Importantly, the recently acquired conventional Canadian assets are expected to enhance output significantly. However, CNQ s exposure to the inherently cyclical and volatile E&P sector offsets these strengths and remains a key area of concern, in our view. The company’s rising operating costs add to the bearish sentiment. “
Costco Wholesale (NASDAQ:COST) had its neutral rating reaffirmed by analysts at Zacks. They currently have a $123.00 price target on the stock.
salesforce.com, inc. (NYSE:CRM) had its neutral rating reaffirmed by analysts at Zacks. Zacks currently has a $57.00 price target on the stock. Zacks’ analyst wrote, “Salesforce’s adjusted loss per share in fiscal first-quarter 2015 compared unfavorably with the Zacks Consensus Estimate. Revenues, however, surpassed the consensus mark and increased on a year-over-year basis, primarily impacted by growth across all it business segments and Salesforce ExactTarget Marketing Cloud platform. The company provided positive second-quarter revenue guidance and raised the fiscal 2015 guidance as well. Moreover, we consider the rapid adoption of Salesforce1 Customer Platform to be a positive for the company. Also, strategic acquisitions and the resultant synergies are expected to benefit in the long run. However, competition from Oracle and SAP, continued weakness in Europe, currency headwinds and increasing investments could pose challenges, going forward. Thus, we reiterate our Neutral recommendation on Salesforce.”
Endo International PLC (NASDAQ:ENDP) had its neutral rating reiterated by analysts at Zacks. They currently have a $71.00 price target on the stock. Zacks’ analyst wrote, “Endo reported higher-than-expected earnings but lower-than-expected revenues in the first quarter of 2014 primarily due to lower sales of Lidoderm, Fortesta Gel and Opana ER. The company issued an encouraging 2014 outlook for both revenues and earnings. Endo is looking to combat the threat of genericization by entering into deals/making acquisitions. The acquisition of Paladin Labs is aimed at combating declining revenues due to generic competition. The acquisitions of DAVA Pharma and Grupo Farmaceutico Somar will expand its portfolio further, following closure. We believe that the stock is fairly valued at current levels and hence retain our Neutral recommendation on the stock.”
Fastenal Company (NASDAQ:FAST) had its neutral rating reissued by analysts at Zacks. The firm currently has a $48.00 target price on the stock. Zacks’ analyst wrote, “Fastenal’s earnings of $0.44 per share in the second quarter were in line with the Zacks Consensus Estimate. Earnings grew 7.3% year over year as a strong top line performance was offset by weak margins. Though sales marginally missed the consensus mark, it grew 12.1%. After struggling for several quarters, Fastenal’s top line turned around in 2014 as underlying markets improved, vending re-vamped, sales improvement efforts showed results and comparisons eased. However, Fastenal’s margins are contracting as management’s focus shifts away to top line improvement. In-fact, management warned that gross margin could remain at the lower end of long term range and maybe even fall below it in the short term. We therefore remain on the sidelines due to gross margin concerns.”
La Jolla Pharmaceutical Company (NASDAQ:LJPC) had its buy rating reaffirmed by analysts at Wedbush.
Royal Dutch Shell Plc (LON:RDSB) had its outperform rating reaffirmed by analysts at RBC Capital. They currently have a GBX 2,700 ($46.22) price target on the stock.
Sarepta Therapeutics (NASDAQ:SRPT) had its neutral rating reissued by analysts at Zacks. They currently have a $23.00 target price on the stock. Zacks’ analyst wrote, “Sarepta reported a loss of $0.66 per share in the first quarter, narrower than the Zacks Consensus Estimate of a loss of $0.80 per share but wider than the year-ago loss of $0.46 per share. First quarter revenues increased 36.1% from the year-ago quarter to $6.1 million. Based on the new guidance issued by the FDA earlier this year, Sarepta is set to file for marketing approval of its lead pipeline candidate, eteplirsen, by year end for the treatment of Duchene muscular dystrophy. The approval of eteplirsen would be a huge boost for the company – eteplirsen, if developed successfully, would be able to capture a major share of this orphan disease market. However, there are other companies working on DMD treatments. Moreover, we are concerned about Sarepta’s dependence on its DMD program. Based on these factors, we are initiating coverage on Sarepta with a Neutral recommendation.”
WESCO International (NYSE:WCC) had its neutral rating reiterated by analysts at Zacks. They currently have a $88.00 price target on the stock. Zacks’ analyst wrote, “WESCO is one of the largest distributors of electrical products in the U.S. The company’s first quarter 2014 earnings missed the Zacks Consensus Estimate mainly on account of bad weather. WESCO’s strong market position, the turnaround in the industrial and utility markets, gradual recovery in the construction market, the global account model, restructuring benefits and the One WESCO initiative are positive factors. However, results bear a positive correlation to GDP growth, which has been sluggish in recent times. Additionally, while EECOL has been incremental to earnings, it resulted in a significant increase in debts, thus making the shares more risky. We have a Neutral recommendation on WESCO shares.”
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.